Traditional Chinese Medicines

15 February 2025
7 July 2025

Guest editor

  • Baoxue Yang

Pharmacology of Traditional Chinese Medicines (TCM) represents a unique and comprehensive field that integrates the study of medicinal substances derived from natural sources, with the understanding of their pharmacological effects and mechanisms of action. Modern pharmacological research employs a range of techniques, including in vitro and in vivo studies, as well as clinical trials, to elucidate the active components, pharmacological effects, and safety profiles of TCM substances, which has led to the discovery of new drugs and therapeutic strategies, as well as a deeper understanding of the molecular basis of TCM.

To drive innovation and potential novel therapeutic breakthroughs in TCM, Basic & Clinical Pharmacology & Toxicology (BCPT) will host a special collection focusing on pharmacology and toxicology in TCM. Original articles, focused reviews and short communications from the field of TCM are considered for this special collection. Please consult the BCPT author guidelines and the most recent “BCPT policy for experimental and clinical studies” and the BCPT policy for natural products “BCPT perspectives on studies involving natural products, traditional Chinese medicine and systems pharmacology” for more information.

Submission deadline: 31 December 2025

Contact information:

Baoxue Yang: [email protected]

Articles

Open Access

Bruceine A Inhibits Cell Proliferation by Targeting the USP13/PARP1 Signalling Pathway in Multiple Myeloma

Bruceine A Inhibits Cell Proliferation by Targeting the USP13/PARP1 Signalling Pathway in Multiple Myeloma

USP13 is a promising therapeutic target for cellular proliferation in multiple myeloma. Bruceine A can retard the development of multiple myeloma by targeting USP13/PARP1-mediated DNA damage repair and triggering cell apoptosis.